Predicting Ultrasound-Guided Thoracic PVB Success in Herpetic Neuralgia
Predictors of Response to Ultrasound-Guided Thoracic Paravertebral Nerve Block in Patients With Herpetic Neuralgia
Beni-Suef University
140 participants
Feb 1, 2025
INTERVENTIONAL
Conditions
Summary
This study aims to fill the knowledge gap by investigating the predictors of success for TPVB in patients with herpetic neuralgia. By identifying demographic, clinical, previous medications and procedural factors associated with positive outcomes, this research seeks to enhance the efficacy of TPVB and improve pain management strategies for patients suffering from herpetic neuralgia.
Eligibility
Inclusion Criteria6
- Adults aged from18 to 70 years
- Diagnosed with herpetic neuralgia.
- Able and willing to provide informed consent.
- ASA I - II
- One dermatomal affection
- Thoracic distribution
Exclusion Criteria3
- Contraindications to TPVB as ( Infection at site of injection, empyema , coagulopathy and neoplastic lesion occupying the paravertebral space)
- Known allergies to study medications (bupivacaine, Dexamethasone).
- Severe comorbidities that could interfere with study participation.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The patients will receive ultrasound-guided TPVB with 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone (10 mL volume)
ultrasound-guided TPVB with 10 mL of saline without knowing which treatment they are receiving, maintaining blinding throughout the study.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06761924